AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2020
Feb 21, 2020
32883_dirs_2020-02-20_f24e4c49-a9a7-4745-a031-a76ab277b878.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2020-01-30
Reporting Person: RIOUX PATRICE (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-01-30 | Stock Options | $16.80 | A | 6125 | Acquired | 2030-01-30 | Common Stock (6125) | Direct |
Footnotes
F1: Stock Options vesting commenced on January 1, 2020 as follows: 510 on January 31, 2020 and each subsequent month-end thereafter.